Palbociclib HCl

Overview

Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation. PD 0332991 is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) (IC50=0.011 μmol/L) and Cdk6 (IC50=0.016 μmol/L), having no activity against a panel of 36 additional protein kinases.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | CDK

Product Information

• Catalog No.: B2693-462758
• CAS No.: 827022-32-2
• Molecular Formula: C24H29N7O2.HCl
• Molecular Weight: 483.99
• Purity: >98%

Source

Original product source